EP1551452A4 - COMPOSITIONS AND METHODS FOR THERAPEUTIC TREATMENT - Google Patents
COMPOSITIONS AND METHODS FOR THERAPEUTIC TREATMENTInfo
- Publication number
- EP1551452A4 EP1551452A4 EP03742338A EP03742338A EP1551452A4 EP 1551452 A4 EP1551452 A4 EP 1551452A4 EP 03742338 A EP03742338 A EP 03742338A EP 03742338 A EP03742338 A EP 03742338A EP 1551452 A4 EP1551452 A4 EP 1551452A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- therapeutic treatment
- therapeutic
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US189025 | 1988-05-02 | ||
US18902502A | 2002-07-01 | 2002-07-01 | |
PCT/US2003/020604 WO2004002528A1 (en) | 2002-07-01 | 2003-06-30 | Compositions and methods for therapeutic treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1551452A1 EP1551452A1 (en) | 2005-07-13 |
EP1551452A4 true EP1551452A4 (en) | 2006-08-30 |
Family
ID=29999592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03742338A Withdrawn EP1551452A4 (en) | 2002-07-01 | 2003-06-30 | COMPOSITIONS AND METHODS FOR THERAPEUTIC TREATMENT |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1551452A4 (pl) |
JP (1) | JP2005534679A (pl) |
KR (1) | KR20050059001A (pl) |
CN (1) | CN1678348A (pl) |
AU (1) | AU2003279657A1 (pl) |
BR (1) | BR0312484A (pl) |
CA (1) | CA2491427A1 (pl) |
IL (1) | IL166062A0 (pl) |
MX (1) | MXPA05000271A (pl) |
PL (1) | PL374431A1 (pl) |
RU (1) | RU2005101622A (pl) |
WO (1) | WO2004002528A1 (pl) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004003144A2 (en) | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
AU2005229492A1 (en) * | 2004-03-30 | 2005-10-13 | Rigshospitalet | Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors |
DK1737428T3 (en) * | 2004-03-31 | 2017-10-09 | Univ Utah Res Found | MACROMOLECULAR ADMINISTRATION SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES |
AU2006294663B2 (en) | 2005-09-26 | 2012-03-22 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
EP2373343B1 (en) * | 2008-12-19 | 2015-02-11 | Philogen S.p.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
CN106659784B (zh) | 2014-07-08 | 2022-03-29 | 桑福德伯纳姆医学研究所 | Psgl-1调控剂及其用途 |
MX2018008144A (es) * | 2016-01-08 | 2018-11-09 | Bioalliance Cv | Anticuerpos tetravalentes anti ligando-1 de glicoproteina p-selectina (psgl-1) y usos de estos. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998011918A1 (en) * | 1996-09-18 | 1998-03-26 | Research Corporation Technologies, Inc. | Use of antibodies to cd45r leukocyte antigens for immunomodulation |
WO2001085205A1 (en) * | 2000-05-11 | 2001-11-15 | National Tsing Hua University | Compositions and methods for induction of active autoimmunity |
WO2001087334A1 (en) * | 2000-05-15 | 2001-11-22 | Pharmacia Italia S.P.A. | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
WO2002053700A2 (en) * | 2000-12-29 | 2002-07-11 | Bio-Technology General Corp. | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
WO2002059264A2 (en) * | 2000-12-29 | 2002-08-01 | Bio-Technology General Corp. | Specific human antibodies for selective cancer therapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05244987A (ja) * | 1992-02-28 | 1993-09-24 | Unitika Ltd | 抗硫酸化チロシン抗体,その製造方法及び抗硫酸化チロシンモノクローナル抗体を産生するハイブリドーマ |
DE69904831T2 (de) * | 1998-07-13 | 2003-11-06 | Univ Texas | Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten |
CA2347119A1 (en) * | 1998-10-30 | 2000-05-11 | Genetics Institute, Inc. | Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
-
2003
- 2003-06-30 KR KR1020047021602A patent/KR20050059001A/ko not_active Application Discontinuation
- 2003-06-30 MX MXPA05000271A patent/MXPA05000271A/es unknown
- 2003-06-30 WO PCT/US2003/020604 patent/WO2004002528A1/en active Application Filing
- 2003-06-30 AU AU2003279657A patent/AU2003279657A1/en not_active Abandoned
- 2003-06-30 CA CA002491427A patent/CA2491427A1/en not_active Abandoned
- 2003-06-30 JP JP2004518133A patent/JP2005534679A/ja active Pending
- 2003-06-30 CN CNA03820441XA patent/CN1678348A/zh active Pending
- 2003-06-30 RU RU2005101622/15A patent/RU2005101622A/ru not_active Application Discontinuation
- 2003-06-30 BR BRPI0312484-3A patent/BR0312484A/pt not_active IP Right Cessation
- 2003-06-30 EP EP03742338A patent/EP1551452A4/en not_active Withdrawn
- 2003-06-30 PL PL03374431A patent/PL374431A1/pl not_active Application Discontinuation
-
2004
- 2004-12-30 IL IL16606204A patent/IL166062A0/xx unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998011918A1 (en) * | 1996-09-18 | 1998-03-26 | Research Corporation Technologies, Inc. | Use of antibodies to cd45r leukocyte antigens for immunomodulation |
WO2001085205A1 (en) * | 2000-05-11 | 2001-11-15 | National Tsing Hua University | Compositions and methods for induction of active autoimmunity |
WO2001087334A1 (en) * | 2000-05-15 | 2001-11-22 | Pharmacia Italia S.P.A. | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
WO2002053700A2 (en) * | 2000-12-29 | 2002-07-11 | Bio-Technology General Corp. | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
WO2002059264A2 (en) * | 2000-12-29 | 2002-08-01 | Bio-Technology General Corp. | Specific human antibodies for selective cancer therapy |
Non-Patent Citations (1)
Title |
---|
See also references of WO2004002528A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN1678348A (zh) | 2005-10-05 |
EP1551452A1 (en) | 2005-07-13 |
JP2005534679A (ja) | 2005-11-17 |
AU2003279657A1 (en) | 2004-01-19 |
CA2491427A1 (en) | 2004-01-08 |
RU2005101622A (ru) | 2006-01-27 |
IL166062A0 (en) | 2006-01-15 |
WO2004002528A1 (en) | 2004-01-08 |
MXPA05000271A (es) | 2005-03-31 |
PL374431A1 (pl) | 2005-10-17 |
BR0312484A (pt) | 2008-01-08 |
KR20050059001A (ko) | 2005-06-17 |
WO2004002528A9 (en) | 2004-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0201850D0 (en) | Therapeutic treatment | |
GB0216321D0 (en) | Therapeutic treatment | |
IL172194A0 (en) | Methods and compositions for treating amyloid-related diseases | |
GB0316912D0 (en) | Therapeutic treatment | |
AU2003278775A8 (en) | Porifera-based therapeutic compositions for treating and preventing skin diseases | |
GB0320806D0 (en) | Therapeutic treatment | |
AU2003287443A8 (en) | Compositions and methods for pain reduction | |
HK1078784A1 (en) | Therapeutic treatment | |
SI1545256T1 (sl) | Naprava za terapevtsko zdravljenje | |
GB0223367D0 (en) | Therapeutic treatment | |
GB0303609D0 (en) | Novel therapeutic method and compositions | |
AU2003232044A8 (en) | Composition and method for dermatological treatment | |
IL166062A0 (en) | Compositions and methods for therapeutic treatment | |
GB0210464D0 (en) | Therapeutic treatment | |
AU2003275433A8 (en) | Compositions and methods for treating pain | |
GB0307863D0 (en) | Therapeutic treatment | |
AU2003291730A8 (en) | Methods and compositions for treating neurodegenerative diseases | |
EP1569928A4 (en) | THERAPEUTIC COMPOUNDS AND METHOD | |
GB0327050D0 (en) | Therapeutic methods compositions and uses | |
EP1583543A4 (en) | METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA | |
GB0313772D0 (en) | Therapeutic treatment | |
GB0303600D0 (en) | Novel therapeutic method and compositions | |
GB0221712D0 (en) | Methods of treatment | |
GB0205826D0 (en) | Therapeutic compositions and methods | |
IL163878A0 (en) | Compositions and methods for treating mdma-inducedtoxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050118 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1080710 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060731 |
|
17Q | First examination report despatched |
Effective date: 20070705 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20080909 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1080710 Country of ref document: HK |